8-K current report · filed Nov 5, 2026

Natera Inc (NTRA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1Item EX-99.2NTRA overview

Short answer

Natera Inc (NTRA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026.

Natera Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026
  • Investor presentation furnished alongside earnings release, providing supplemental operating and financial detail

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $794.0M, up 34.1% YoY, with reported tests up 23.0% to 1,024,800
  • Oncology tests 339,500, up 60.9% YoY, while clinical MRD units grew 32,700 sequentially
  • Gross margin 64.7% versus 64.9% YoY, with non-GAAP margin up 1.4% sequentially excluding revenue-accrual changes
  • Net loss narrowed to $59.9M, or $0.42 per share, from $87.5M, or $0.64 per share
  • 2026 revenue guidance raised to $3.005B-$3.035B, with positive cash flow expected

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 revenue $794.0M, up ~34% year over year, with total tests exceeding 1.09M
  • Clinical MRD oncology volume ~316K, up >56% year over year and ~33K sequentially
  • Gross margin 64.7%, while ex-true-up margin reached 63.2%, up ~140 basis points sequentially
  • 2026 revenue guidance raised to $3.005B-$3.035B, a $140M midpoint increase
  • 2029 revenue target of $6B, supported by oncology, Japan expansion, pharma partnerships, and data licensing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Natera Inc 8-K filings

Get the next NTRA 8-K as it lands

Follow NTRA for push alerts, or ask the research agent what this filing means.